@article{15bc31d70ef24c369a1cd12600ea67fe,
title = "Synthetic biology: at the crossroads of genetic engineering and human therapeutics—a Keystone Symposia report",
abstract = "Synthetic biology has the potential to transform cell- and gene-based therapies for a variety of diseases. Sophisticated tools are now available for both eukaryotic and prokaryotic cells to engineer cells to selectively achieve therapeutic effects in response to one or more disease-related signals, thus sparing healthy tissue from potentially cytotoxic effects. This report summarizes the Keystone eSymposium “Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics,” which took place on May 3 and 4, 2021. Given that several therapies engineered using synthetic biology have entered clinical trials, there was a clear need for a synthetic biology symposium that emphasizes the therapeutic applications of synthetic biology as opposed to the technical aspects. Presenters discussed the use of synthetic biology to improve T cell, gene, and viral therapies, to engineer probiotics, and to expand upon existing modalities and functions of cell-based therapies.",
author = "Jennifer Cable and Leonard, {Joshua N.} and Lu, {Timothy K.} and Zhen Xie and Chang, {Matthew Wook} and Fern{\'a}ndez, {Luis {\'A}ngel} and Lora, {Jos{\'e} M.} and Kaufman, {Howard L.} and Quintana, {Francisco J.} and Roger Geiger and {F. Lesser}, Cammie and Lynch, {Jason P.} and Hava, {David L.} and Cornish, {Virginia W.} and Lee, {Gary K.} and Breanna DiAndreth and Michael Fero and Rajkamal Srivastava and {De Coster}, Tim and Roybal, {Kole T.} and Rackham, {Owen J.L.} and Samira Kiani and Iowis Zhu and Hernandez-Lopez, {Rogelio A.} and Tingxi Guo and Chen, {William C.W.}",
note = "Funding Information: Research in the F.J.Q. lab is supported by Grants NS102807, ES02530, ES029136, AI126880, and AI149699 from the NIH; RG4111A1 and JF2161-A-5 from the NMSS; and PA-1604-08459 from the International Progressive MS Alliance and the Jennifer Oppenheimer Cancer Research Initiative. Funding Information: W.C.W.C. was supported by the Pfizer-MIT RCA Synthetic Biology Program (CHO2.0 and Precision Post-Translational Modification). W.C.W.C. was supported in part by the NIH Ruth L. Kirschstein NRSA postdoctoral fellowship (5T32HL007208). Funding Information: Work by the S.K. group is primarily supported by an RO1 grant from the National Institute of Biomedical Imaging and Bioengineering (R01EB024562), a startup fund by the School of Biological and Health Systems Engineering of the Ira. A Fulton Schools of Engineering at Arizona State University; and the Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine (NIH/NIDDK P30DK120531). Funding Information: Work in the laboratory of L.A.F. was supported by Grant BIO2017-89081-R from Agencia Espa{\~n}ola de Investigaci{\'o}n (AEI/MICIU/FEDER, EU) and CSIC-SynLogic contract ref. 20182256. Funding Information: gramme (NUHSRO/2020/077/MSC/02/SB), the National Medical Research Council of Singapore (CBRG11nov109), the Agency for Science, Technology and Research (A∗STAR) of Singapore (112 177 0040), the U.S. Air Force (FA/2,386/12/1/4,055), the U.S. Defense Threat Reduction Agency (HDTRA1-13-0037), and the National Research Foundation of Singapore (NRF-NRFI05-2019-0004). Funding Information: R.G. received research funding from Synlogic Inc. S.K. is a founder and CEO of GenexGen Inc. L.A.F. is an inventor on patent and patent application related to the use of T3SS for antibody protein translocation into mammalian cells (US 8,623349 B2, EP20383142). Funding Information: M.W.C. was supported by the Synthetic Biology Translational Funding Information: R.G. is supported in part by Synlogic Inc., the European Research Council (803150), and Swiss Cancer Research (KFS-4593-08-2018). Funding Information: M.W.C. was supported by the NUS Medicine Synthetic Biology Translational Research Programme (NUHSRO/2020/077/MSC/02/SB), the National Medical Research Council of Singapore (CBRG11nov109), the Agency for Science, Technology and Research (A*STAR) of Singapore (112 177 0040), the U.S. Air Force (FA/2,386/12/1/4,055), the U.S. Defense Threat Reduction Agency (HDTRA1-13-0037), and the National Research Foundation of Singapore (NRF-NRFI05-2019-0004). R.G. is supported in part by Synlogic Inc., the European Research Council (803150), and Swiss Cancer Research (KFS-4593-08-2018). Research in the F.J.Q. lab is supported by Grants NS102807, ES02530, ES029136, AI126880, and AI149699 from the NIH; RG4111A1 and JF2161-A-5 from the NMSS; and PA-1604-08459 from the International Progressive MS Alliance and the Jennifer Oppenheimer Cancer Research Initiative. Work by the S.K. group is primarily supported by an RO1 grant from the National Institute of Biomedical Imaging and Bioengineering (R01EB024562), a startup fund by the School of Biological and Health Systems Engineering of the Ira. A Fulton Schools of Engineering at Arizona State University; and the Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine (NIH/NIDDK P30DK120531). W.C.W.C. was supported by the Pfizer-MIT RCA Synthetic Biology Program (CHO2.0 and Precision Post-Translational Modification). W.C.W.C. was supported in part by the NIH Ruth L. Kirschstein NRSA postdoctoral fellowship (5T32HL007208). Work in the laboratory of L.A.F. was supported by Grant BIO2017-89081-R from Agencia Espa?ola de Investigaci?n (AEI/MICIU/FEDER, EU) and CSIC-SynLogic contract ref. 20182256. Publisher Copyright: {\textcopyright} 2021 New York Academy of Sciences.",
year = "2021",
month = dec,
doi = "10.1111/nyas.14710",
language = "English (US)",
volume = "1506",
pages = "98--117",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",
}
